- aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
- aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
- aTyr Pharma to Present at Upcoming Investor Conferences
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma to Participate in April Investor Conferences
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
- aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
- aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
- aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
More ▼
Key statistics
On Wednesday, aTyr Pharma Inc (LIFE:NAQ) closed at 1.86, -27.06% below its 52-week high of 2.55, set on May 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.95 |
---|---|
High | 1.95 |
Low | 1.86 |
Bid | 1.83 |
Offer | 1.97 |
Previous close | 1.86 |
Average volume | 803.99k |
---|---|
Shares outstanding | 69.01m |
Free float | 67.23m |
P/E (TTM) | -- |
Market cap | 128.36m USD |
EPS (TTM) | -0.9029 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼